BioVenture
- Company typePrivate
- Founded2013
- HeadquartersSuzhou, China
- Headcount101–250
- GTM typeB2B
- OfferingServices
BioVenture firmographics
Firmographics- Name
- BioVenture
- Legal name
- 苏州工业园区元生创业投资管理有限公司
- Website
- https://bioventure.com.cn
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
BioVenture industry classification
Industry- Product category
- Healthcare Venture Capital
- NAICS
- Other Financial Vehicles (525990)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
Keywords
Where BioVenture is headquartered
LocationHeadquarters
- HQ city
- Suzhou
- HQ country
- China
- HQ region
- Asia
Offices5 records
Markets served
BioVenture business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Management Fees: Annual management fees based on committed capital under management
- Carried Interest: Performance-based carried interest from successful portfolio exits and IPOs. 19 portfolio companies have listed on HKEX, STAR Board, and other exchanges.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Annual | VC fund management and performance fees |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
BioVenture product offering
Product offeringCore offering
BioVenture (元生创投) is a China-based venture capital firm that manages RMB and USD investment funds focused exclusively on early and growth-stage healthcare companies. It deploys capital across four areas—new drug R&D, medical devices, IVD and precision medicine, and healthcare services—and supplements investment with hands-on post-investment management and value-added services through the BioBAY ecosystem.
Product overview
BioVenture (元生创投) is a healthcare-focused venture capital firm offering investment fund management services. The firm operates multiple investment funds including a RMB fund (新建元生物产业基金) and a USD Fund II, targeting early and growth-stage healthcare companies across biotech, medical devices, IVD, and healthcare services. The firm provides capital deployment, post-investment management, and value-added services to portfolio companies through its network and platform resources.
Differentiator
Problem solved
Functional benefit
Products and services
- 新建元生物产业基金 (Xinjianyuan Bio-Industry Fund) BioVenture's first RMB fund focused on early and growth-stage life sciences investments, covering new drug R&D, medical devices, IVD, and healthcare services. The fund has a 7-year term and invests across the firm's four healthcare verticals.
- YuanBio USD Fund II BioVenture's second USD-denominated fund investing in overseas healthcare innovation companies. Used to participate in cross-border rounds such as the Series A of BestView Laser in 2022.
Quantifiable outcome
- 19 portfolio companies successfully listed on exchanges (HKEX, STAR Board, etc.)
- +1 more outcomes
Companies that use BioVenture
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles2 records
BioVenture technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
BioVenture partnerships and signals
Strategic signalScale indicators5 records
Recent moves7 records
Expansion highlights5 records
BioVenture competitors and assessment
Company assessmentDirect peers
- Qiming Venture Partners: Leading China VC with a dedicated healthcare practice spanning new drug R&D and medical devices. Comparable in stage focus (early/growth), sector, and Chinese institutional LP base.
- Legend Capital (君联资本): Large China VC/PE firm with a substantial healthcare practice, comparable in stage and sector focus. Competes for the same growth-stage healthcare deals in China.
- LYFE Capital: Healthcare-dedicated venture capital firm investing across drugs, devices, and diagnostics in China. Closest direct peer given matching focus on early-to-growth Chinese healthcare with comparable AUM scale.
- Highlight Capital (高特佳投资): China's most prominent healthcare-dedicated PE/VC, investing across pharma, devices, and IVD. Direct competitor for healthcare-specific deal flow and LP capital.
- Cowin Capital (同创伟业): Shenzhen-headquartered Chinese VC with a meaningful healthcare practice (drugs, devices, diagnostics). Directly comparable in size, stage focus, and target deal universe.
- Loyal Valley Capital (正心谷资本): China-focused active investor with significant healthcare allocation across biotech and innovative drugs. Competes on similar RMB-denominated healthcare venture opportunities.
Broad incumbents
- IDG Capital: Major cross-stage China VC with healthcare exposure across biotech and devices. Competes for healthcare deal flow but as part of a broader technology and consumer mandate.
- CDH Investments (鼎晖投资): Large Chinese PE/VC platform with a healthcare practice covering pharma and medical devices. Larger and more diversified than BioVenture, but competes for growth-stage Chinese healthcare deals.
- OrbiMed: Global healthcare-dedicated investment firm with a long-standing China presence. Competes on healthcare venture deals but operates at much larger fund sizes and global mandate.
- Hillhouse Capital: Mega-asset manager with healthcare practice that competes across the same Chinese healthcare opportunity set, but at materially larger scale and broader portfolio mandate.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
BioVenture financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioVenture leadership team
Management profileNumber of profiles
Profiles9 records
BioVenture funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioVenture M&A and investment
M&A and investmentM&A
Investments189 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioVenture
What does BioVenture do?
BioVenture (元生创投) is a China-based venture capital firm that manages RMB and USD investment funds focused exclusively on early and growth-stage healthcare companies. It deploys capital across four areas—new drug R&D, medical devices, IVD and precision medicine, and healthcare services—and supplements investment with hands-on post-investment management and value-added services through the BioBAY ecosystem.
Is BioVenture a public or private company?
BioVenture is a private company. It is classified as management employee owned and is currently operating.
When was BioVenture founded?
BioVenture was founded in 2013. It employs 101 to 250 people.
Where is BioVenture based?
BioVenture is headquartered in Suzhou, China, in the Asia region.
How does BioVenture make money?
Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest.
Who are BioVenture's main competitors?
Direct peers on record are Qiming Venture Partners, Legend Capital (君联资本), LYFE Capital, Highlight Capital (高特佳投资), Cowin Capital (同创伟业) and Loyal Valley Capital (正心谷资本). Broad incumbents are IDG Capital, CDH Investments (鼎晖投资), OrbiMed and Hillhouse Capital.
Does BioVenture have an API?
No public API is recorded for BioVenture.
What industry is BioVenture in?
BioVenture's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 525990 and its SIC code is 6282.